IDXX

IDEXX Laboratories, Inc.

$557.93

+0.38% 2026-10-20

Health CareS&P 500

1M 3M 6M 1Y 2Y

IDXXSPY

+7.2%

+9.0%

+1.0%

-1.9%

YTD

-17.5%

-13.3%

Live chart

Loading live chart…

Grades vs sector

Momentum

17th pct in sector

12-1 return: -17.0%
Percentile within its GICS sector across the S&P 1500.

Growth

57th pct in sector

B-

Revenue growth (YoY): +9.7%
Percentile within its GICS sector across the S&P 1500.

Value

14th pct in sector

D-

Forward E/P: 3.0% · EBITDA/EV: 3.6%
Percentile within its GICS sector across the S&P 1500.

Profitability

91st pct in sector

Profit margin: +25.0% · Return on equity: +74.2%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Top 15

rank 413 of 499 · 12-1 momentum % -12.9

Momentum Blend

not in the current book

New Highs Growth

not ranked (outside this model's universe or screens)

Conviction 20

not in the current book

News

More news

IDEXX Laboratories (IDXX) Rebounds On Jefferies Support, Is It Still 20% Undervalued?

Simply Wall St. · 7h ago

Idexx Laboratories Now #251 Largest Company, Surpassing Waters

Nasdaq · 15h ago

Key stats

Market cap$44.0B

P/E (trailing)39.2

P/E (forward)33.3

52-week range500.61 – 769.98

Revenue growth (YoY, latest qtr)+9.7%

Dividend yield0.00%

Analyst consensusBuy (12)

Mean price target$698.00 (+25%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Leans expensive

Model read-out from the numbers below, not advice. Score -1 (DCF counts double).

▼DCF (base case)below the price by 57%

▼Forward P/E vs sector33.3x vs median 17.6x

▲Piotroski F-score8/9

▲Altman Z20.1 (safe)

▲Net debt / EBITDA0.2x

▲Analyst target+25% (12 analysts)

Discounted cash flow

Bear

$161

-71%

growth 4% · disc. 13.0% · term. 2.0%

Base

$240

-57%

growth 9% · disc. 12.0% · term. 2.5%

Bull

$332

-40%

growth 12% · disc. 11.0% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 20% a year for 10 years.

Implied

+20%/yr

FCF, last 3 yrs

+39%/yr

FCF, last 5 yrs

+14%/yr

Revenue, last 3 yrs

+9%/yr

Revenue, last 5 yrs

+10%/yr

Same inputs as the DCF above: trailing free cash flow 1.3B, 12.0% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.55 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9× · 70th pct

39.2×
pricier

Forward P/E

sector median 17.6× · 87th pct

33.3×
pricier

EV / EBITDA

sector median 15.8× · 83rd pct

27.4×
pricier

Price / sales

sector median 3.1× · 88th pct

9.7×
pricier

Price / book

sector median 3.5× · 96th pct

27.3×
pricier

FCF yield

sector median 4.1% · 34th pct

2.9%
pricier

Forward EPS $16.74 vs trailing $14.23 (+18% expected growth). Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

62.4%

Operating margin

32.0%

FCF margin

27.5%

Net margin

25.0%

Return on equity

70.7%

Return on invested capital

62.6%

Net debt / EBITDA

0.2×

Current ratio

1.2×

Interest cover

38.6×

Cash conversion (OCF/NI)

1.2×

Piotroski F-score 8/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✓ Gross margin improved✓ Asset turnover improved

Altman Z-score 20.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$698

+25%

Analysts

Buy

Range

$470–$805

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$4.3B	$1.1B	$1.1B
2024	$3.9B	$887.9M	$808.1M
2023	$3.7B	$845.0M	$772.9M
2022	$3.4B	$679.1M	$394.1M
2021	$3.2B	$744.8M	$636.0M
2020	$2.7B	$581.8M	$541.1M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +8.5%.

Earnings

Next report: 2026-11-02 · before open · EPS est 3.72

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-04	3.93	4.27	+8.5%
2026-05-05	3.41	3.47	+1.7%
2026-02-02	2.94	3.08	+4.8%
2025-11-03	3.15	3.40	+8.1%
2025-08-04	3.30	3.63	+10.0%
2025-05-01	2.84	2.96	+4.1%
2025-02-03	2.40	2.62	+9.2%
2024-10-31	2.69	2.80	+4.3%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$1.2B	+9.7%
2026-03-31	$1.1B	–
2025-12-31	$1.1B	–
2025-09-30	$1.1B	–
2025-06-30	$1.1B	–

Analyst actions

JP Morgan

2026-10-16 · main

Overweight → Overweight
PT $750

Keybanc

2026-10-12 · init

→ Sector Weight

Barclays

2026-08-11 · main

Overweight → Overweight
PT $710

UBS

2026-08-05 · main

Neutral → Neutral
PT $670

Citigroup

2026-08-05 · main

Neutral → Neutral
PT $670

UBS

2026-07-27 · main

Neutral → Neutral
PT $620

Insider trades

Kingsley Lawrence D

Director · 2026-09-04

SELL
$1.2M

None

None · None

SELL
–

None

None · None

SELL
–

Stats refreshed 2026-10-20 18:02:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.

How it works Disclaimer Terms Privacy Data status